These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29191664)

  • 21. Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed/refractory neuroblastomas post autologous hematopoietic stem cell transplantation.
    Mohseni R; Mahdavi Sharif P; Behfar M; Shojaei S; Shoae-Hassani A; Jafari L; Khosravi A; Nikfetrat Z; Hamidieh AA
    Sci Rep; 2024 Sep; 14(1):20971. PubMed ID: 39251669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators.
    Pockley AG; Lindsay JO; Foulds GA; Rutella S; Gribben JG; Alexander T; Snowden JA
    Front Immunol; 2018; 9():646. PubMed ID: 29670622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
    Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission With Donor Lymphocyte Infusion in a Child With Marrow Relapse After Haploidentical Stem Cell Transplantation for Relapsed Stage 4 Neuroblastoma.
    Liu AP; Leung RY; Cheuk KL; Lee PP; Chiang AK; Ha SY; Chan GC
    Pediatr Blood Cancer; 2016 Aug; 63(8):1477-9. PubMed ID: 27100283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune reconstitution after autologous purged bone marrow transplantation in children.
    Kamani N; Kattamis A; Carroll A; Campbell D; Bunin N
    J Pediatr Hematol Oncol; 2000; 22(1):13-9. PubMed ID: 10695816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.
    Khandelwal P; Millard HR; Thiel E; Abdel-Azim H; Abraham AA; Auletta JJ; Boulad F; Brown VI; Camitta BM; Chan KW; Chaudhury S; Cowan MJ; Angel-Diaz M; Gadalla SM; Gale RP; Hale G; Kasow KA; Keating AK; Kitko CL; MacMillan ML; Olsson RF; Page KM; Seber A; Smith AR; Warwick AB; Wirk B; Mehta PA
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1342-1349. PubMed ID: 28450183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High-dose therapy followed by auto HSCT in children--with advanced neuroblastoma in four transplant centres in Poland].
    Zaucha-Prazmo A; Drabko K; Wójcik B; Choma M; Kałwak K; Gorczyńska E; Turkiewicz D; Słociak M; Ussowicz M; Dyla A; Chybicka A; Goździk J; Ratajczak M; Styczyński J; Debski R; Wysocki M; Kowalczyk J
    Med Wieku Rozwoj; 2006; 10(3 Pt 1):775-84. PubMed ID: 17317908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
    Rueff J; Medinger M; Heim D; Passweg J; Stern M
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
    Emberesh M; Rubinstein JD; Young J; Benoit SW; Dandoy CE; Weiss BD
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28852. PubMed ID: 33381917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children.
    Bartelink IH; Belitser SV; Knibbe CA; Danhof M; de Pagter AJ; Egberts TC; Boelens JJ
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):305-13. PubMed ID: 23092812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
    Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune restoration following hematopoietic stem cell transplantation: an evolving target.
    Auletta JJ; Lazarus HM
    Bone Marrow Transplant; 2005 May; 35(9):835-57. PubMed ID: 15778723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation].
    Niedzielska E; Wójcik D; Barg E; Pietras W; Sega-Pondel D; Doroszko A; Niedzielska M; Skarzyńska M; Chybicka A
    Med Wieku Rozwoj; 2008; 12(3):761-6. PubMed ID: 19305027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.